5 Key Takeaways
-
1
The biopharma landscape is evolving due to geopolitical pressures, scientific diversification, and changing supply chain expectations.
-
2
Joerg Ahlgrimm, CEO of SK pharmteco, emphasizes the importance of passion and teamwork in developing life-improving drugs.
-
3
Manufacturing in the US is becoming essential for companies seeking reliable market access, impacting supply chain strategies.
-
4
The CDMO sector is experiencing market consolidation, with significant mergers and acquisitions shaping its future.
-
5
SK pharmteco is expanding its capabilities in peptide manufacturing to align with its established small-molecule strategy.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
